Amendment #3 to Project Rider #1 Collaboration Agreement between Magenta Therapeutics, Inc. and National Marrow Donor Program d/b/a Be The Match Biotherapies

Contract Categories: Business Operations › Collaboration Agreements
Summary

Magenta Therapeutics, Inc. and the National Marrow Donor Program (doing business as Be The Match Biotherapies) have agreed to amend their existing collaboration agreement. This amendment extends the agreement's term through December 31, 2021, and updates the payment schedule. Magenta will pay BTMB $17,500 each quarter in 2021 for consulting services, with invoices due on specified dates. The amendment is effective upon the final signature of both parties' authorized representatives.

Read More Arrow
EX-10.10.5 3 d76599dex10105.htm EX-10.10.5 EX-10.10.5

Exhibit 10.10.5

AMENDMENT #3

TO

PROJECT RIDER #1

COLLABORATION AGREEMENT

This Amendment #3 to Project Rider #1 (“Amendment #3”) is entered into effective as of the date of the final signature executing this Amendment #3 (“Amendment #3 Effective Date”) by and between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”) (each a “Party” and collectively the “Parties”).

WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017 and a Project Rider, effective December 6, 2017 (as amended by that certain Amendment #1, effective December 6, 2018 and Amendment #2, effective November 13, 2019, “Project Rider #1”); and

WHEREAS, the Parties agree to extend the Term and Payment Schedule of the Project Rider #1.

NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment as follows:

Amendment to Project Rider #1

 

1.

Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its entirety and replace it with the following to read as follows:

PAYMENT SCHEDULE

 

For Services provided by BTMB during Calendar Year 2021 (January 1, 2021 through December 31, 2021), Magenta will pay BTMB a fixed price quarterly payment of $17,500.   

BTMB will invoice $17,500 every January 15th for consulting services occurring during the period commencing January 1st and ending March 31st.

 

BTMB will invoice $17,500 every April 15th for consulting services commencing April 1st and ending June 30th.

 

BTMB will invoice $17,500 every July 15th for consulting services commencing July 1st and ending September 30th.

 

BTMB will invoice $17,500 every October 15th for consulting services commencing October 1st and ending December 31st.

2.

Delete Section E. TERM. of Project Rider #1 in its entirety and replace it with the following to read as follows:

E. TERM. The term of this Rider shall commence on the Rider effective date set forth above and continue and remain in effect through December 31, 2021.

[Remainder of page intentionally left blank.]

 

2

This Amendment #3 is executed by individuals who are duly authorized to legally bind their respective parties as of the Amendment #3 Effective Date:

 

MAGENTA THERAPEUTICS, INC.    

NATIONAL MARROW DONOR

PROGRAM d/b/a BE THE MATCH

BIOTHERAPIES

By:   /s/ Christina Isacson     By:   /s/ Mary Frey
  Authorized signature       Authorized signature
 

Christina Isacson

      

Mary Frey

  (Typed/Printed Name)       (Typed/Printed Name)
Title:  

Chief Business Officer

     Title:  

Contracts & Procurement Director

Date:  

12/16/20

     Date:  

12/7/2020

 

3